Anti Inflammatory News and Research

RSS

Vioxx may still be the best option for treating some forms of arthritis

Scientists believe that despite the current concerns around anti-inflammatory drugs like Vioxx, they may still be the best option for treating some forms of arthritis.

18 Jan 2006

Alzheimer's may be triggered by neuron division

A new study in mice suggests that Alzheimer's disease (AD) may be triggered when adult neurons try to divide. The finding helps researchers understand what goes wrong in the disease and may lead to new ways of treating it.

18 Jan 2006

FDA warns against buying prescription drugs on the net or overseas

According to the U.S. Food and Drug Administration (FDA), consumers and healthcare professionals who fill out their prescriptions abroad are putting themselves at risk.

17 Jan 2006

Fabricated cancer study published in the Lancet

In a somewhat shocking revelation it has been disclosed that a Norwegian cancer expert made up fictitious patients for an article about treatment of oral cancer published in a leading medical journal.

16 Jan 2006

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

10 Jan 2006

Promising new therapy for ulcerative colitis

For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home.

6 Jan 2006

The role of genes in the development of non-Hodgkin's lymphomas

An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.

15 Dec 2005

Pfizer to fund independent trial on Celebrex and heart risks

Drug company Pfizer Inc., the maker of Celebrex, will pay for an international study of 20,000 people.

14 Dec 2005

COX-2 inhibitors may not be as safe as originally thought

There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in the British Medical Journal.

7 Dec 2005

Short-term use of painkiller drugs does not increase the risk of heart attack

Short-term use of painkiller drugs in the same family as ibuprofen does not increase the risk of having a heart attack.

7 Dec 2005

Findings may help in development of new anti-inflammatory compounds

Virginia Commonwealth University researchers studying the enzyme that triggers inflammation have found that it may be a target for a new class of anti-inflammatory drugs to treat arthritis, asthma, multiple sclerosis, lung and colon cancers and Alzheimer's disease.

2 Dec 2005

Warning labels on high-risk drugs ignored by doctors

In a survey of approximately 930,000 ambulatory care patients, researchers from the Department of Ambulatory Care and Prevention (of Harvard Medical School and Harvard Pilgrim Health Care) and colleagues found that 42 percent received prescriptions for drugs with Black Box Warnings (BBW), the Food and Drug Administration's strongest label for high-risk medication.

21 Nov 2005

Warnings on popular asthma drug could damage drug giant

The U.S. Food and Drug Administration (FDA) is recommending new restrictions on the asthma drug Advair.

21 Nov 2005

Bright light therapy may aid patients with depressive and bipolar disorders

A report in the November Cell Metabolism reveals powerful effects of light on the adrenal glands, a finding that might explain the broad benefits of bright light therapy for a variety of conditions, including sleep and depressive disorders, according to researchers.

14 Nov 2005

Phenolic compounds in olive oil may explain cardiovascular health benefits associated with Mediterranean Diet

Phenolic compounds in olive oil, which have antioxidant, anti-inflammatory and anti-clotting properties, may explain cardiovascular health benefits associated with the so-called Mediterranean Diet, according to a new study in the Nov. 15, 2005, issue of the Journal of the American College of Cardiology.

13 Nov 2005

Taking either COX-2 inhibitors or NSAIDs after a heart attack increases the risk of death

In recent years, evidence has shown that patients treated with selective cyclo-oxygenase-2 (COX-2) inhibitors are at increased risk of heart attack and death. COX-2 inhibitors are used primarily to treat pain and arthritis in patients at risk of gastrointestinal bleeding.

13 Nov 2005

Statins reduce the risk of stroke after carotid artery endarterectomy

Carotid artery endarterectomy (CEA) is the most commonly performed operation to prevent stroke in the United States. However, the operation itself carries a small risk of stroke.

13 Nov 2005

Zyflamend shows promise in the early treatment of prostate cancer

Data from the Columbia University Department of Urology demonstrates that Zyflamend, a unique herbal extract preparation, suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct via a process called "apoptosis."

13 Nov 2005

Non-steroidal anti-inflammatory drugs may prevent the development of oesophageal adenocarcinoma in patients with Barrett's oesophagus

Barrett’s oesophagus is a metaplastic disorder that develops in about 10% of people with chronic gastro-oesophageal reflux disease. Every year about 0.5%-1% of patients with Barrett’s oesophagus develop oesophageal adenocarcinoma.

10 Nov 2005

Use of traction to help treat low back pain has no benefit

"Traction was introduced before it was properly evaluated in high-quality randomized trials, and as an intervention is already part of usual practice,” said lead author Judy M.A. Clarke, M.D. “It is hard to convince health care providers not to use it."

10 Nov 2005